<div id="readability-page-1">Massachusetts biotech companies are tightening their belts as economic uncertainty mounts, pulling in less funding, laying off workers and delaying acquisitions, per a new industry report. Why it matters: The state is one of the world's top producers of drugs treating rare diseases and other conditions, outpacing Chinese competitors. The mix of tariffs, federal funding cuts and other barriers may shrink the region's lead. Driving the news:...</div>

Ultragenyx制药

<p>马萨诸塞州的生物技术公司正面临经济挑战，导致资金减少、裁员和收购推迟。该州在稀有疾病药物生产方面处于领先地位，但由于关税、联邦资金削减和其他障碍，面临失去竞争优势的风险。这一趋势突显了在日益增长的不确定性中，行业所面临的困境</p>

马萨诸塞州的生物技术行业在面临逆风和特朗普削减政策的情况下出现萎缩